Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Liu on the Efficacy of Zidesamtinib in ROS1 Fusion+ NSCLC

November 12th 2025

Stephen Liu, MD, discussed efficacy data with zidesamtinib in ROS1 fusion–positive non-small cell lung cancer that were reported in the ARROS-1 trial.

Dr Camidge on the Efficacy and Safety of Neladalkib in ALK+ Solid Tumors

November 12th 2025

D. Ross Camidge, MD, PhD, discusses safety and efficacy data seen with neladalkib in TKI-naive and -pretreated patients with ALK-positive solid tumors.

Ifinatamab Deruxtecan Development Continues in Phase 3 Study After Robust Results in Pretreated ES-SCLC

November 12th 2025

Based on its previously demonstrated activity and tolerability in ES-SCLC, I-DXd will be examined in the phase 3 IDeate-Lung02 trial.

FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC

November 12th 2025

AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

Treatment Strategies for Stage IIIB/N2 and High-Risk Early-Stage NSCLC

November 11th 2025

Panelists discuss how stage IIIB treatment decisions require individual assessment, with surgery considered for selected T3/T4 tumors but not routinely for N3 disease, while postoperative radiation is generally not recommended.

Integrating Radiation Therapy With Neoadjuvant IO in Early-Stage NSCLC

November 11th 2025

Panelists discuss how to carefully manage radiation therapy after induction immunotherapy in surgically ineligible patients, treating only visible disease and considering additional immunotherapy based on patient tolerance and response.

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

November 10th 2025

The NCCN has released their updated Clinical Practice Guidelines in Oncology for NSCLC.

EGFR PACC Mutation Identification Strategies in NSCLC

November 10th 2025

Panelists discuss how advanced genomic profiling techniques are vital for accurate detection of PACC mutations.

EGFR PACC Mutations in NSCLC

November 10th 2025

Panelists discuss how classifying EGFR mutations into molecular subgroups, including PACC, refines diagnosis and informs targeted treatment decisions.

Frontline STK-012 Plus Pembrolizumab and Chemo Shows Early Promise in PD-L1–Negative NSCLC

November 9th 2025

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

November 6th 2025

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.

Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors

November 5th 2025

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

Dr Lee on the Importance of Multidisciplinary Collaboration in NSCLC Management

November 4th 2025

Percy Lee, MD, discusses the critical nature of multidisciplinary collaboration and notes lingering questions about the optimal use of SABR in NSCLC.

Best Practices for Use of Neoadjuvant Immunotherapy in Resectable Early-Stage NSCLC

November 4th 2025

Panelists discuss how restaging practices vary widely, with most favoring CT imaging over routine invasive restaging, while debating the optimal number of induction cycles (3 vs 4) and timing of surveillance.

Clinical Impact of Incorporation of Immunotherapy and Targeted Therapy in Early-Stage NSCLC

November 4th 2025

Panelists discuss how the rapid integration of immunotherapy and targeted therapies into perioperative care requires constant practice updates and individualized decision-making based on pathologic response and patient characteristics.

Roswell Park Care Network Expands to Albany in Collaboration with St. Peter’s Health Partners

November 3rd 2025

Roswell Park's National Cancer Institute-designated comprehensive cancer center will bring its expertise to the Capital Region.

Lifileucel Displays Antitumor Activity in Advanced Nonsquamous NSCLC

November 3rd 2025

Lifileucel was deemed safe and active in patients with previously treated, advanced nonsquamous NSCLC without certain actionable genetic mutations.

FDA Approval of Zongertinib Marks a Targeted Advancement for Patients With HER2-Mutant NSCLC

November 3rd 2025

Martin Dietrich, MD, PhD, discusses how zongertinib offers a new targeted option for HER2-mutant NSCLC, yielding durable responses and strong CNS activity.

Five Under 5: Top Oncology Videos for the Week of 10/26

November 2nd 2025

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

Cemiplimab Receives Reimbursement in Seven Provinces for NSCLC, Basal Cell Carcinoma

October 31st 2025

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.